Non-replicating expression vectors: Applications in vaccine development and gene therapy

Epidemiology and Infection

Volumn 116, Issue 3, 1996, Pages 241-256

  Limbach, K J ^a   Paoletti, E ^a  

^a Virogenetics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE; VIRUS VECTOR;

ADENOVIRUS; GENE THERAPY; HUMAN; IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; POXVIRUS; RABIES VIRUS; RETROVIRUS; REVIEW; SMALLPOX; VACCINIA VIRUS;

EID: 0029898314     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/s0950268800052547     Document Type: Review

References (87)

1. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia. Proc Natl Acad Sci USA 1982; 79: 4927-31.
2. Mackett M, Smith G, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982; 79: 7415-9.
3. Goebel S, Johnson G, Perkus M, Davis S, Winslow J, Paoletti E. The complete DNA sequence of vaccinia virus. Virol 1990; 179: 247-66.
4. Perkus M, Goebel S, Davis S, Johnson G, Norton E, Paoletti E. Deletion of 55 open reading frames from the termini of vaccinia virus. Virol 1991; 180: 406-10.
5. Smith G, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 1983; 25: 21-8.
6. Blancou J, Kieny M, Lathe R, et al. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 1986; 322: 373-6.
7. Rupprecht C, Wiktor T, Johnston D, et al. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc Natl Acad Sci 1986; 83: 7947-51.
8. Brochier B, Kieny M, Costy F, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991; 354: 520-2.
9. Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies: a link between Jenner and Pasteur. Epidemiol Infect 1996; 116: (accompanying article).
10. Mackett M, Yilma T, Rose J, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science 1985; 227: 433-6.
11. Taylor J, Weinberg R, Tartaglia J, et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virol 1992; 187: 321-8.
12. Yilma T, Hus D, Jones L, et al. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 1988; 242: 1058-61.
13. Riviere M, Tartaglia J, Perkus M, et al. Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants. J Virol 1992; 66: 3424-34.
14. Bowen R, Short W, Cropp C, et al. Protection of horses immunized with recombinant vaccinia-Venezuelan equine encephalitis vaccine. Vaccine Res 1992; 1: 111-21.
15. Neff, J. Vaccinia virus vaccines: Virulence and attenuation of vaccinia strain variation, In: Quinnan G, ed. Vaccinia viruses as vectors for vaccine antigens. New York, New York: Elsevier Science Publishing Co., 1985: 69-75.
16. Morgan A, Mackett M, Finerty S, Arrand J, Scullion F, Epstein M. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol 1988; 25: 189-95.
17. Tartaglia J, Perkus M, Taylor J, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virol 1992; 188: 217-32.
18. Konishi E, Pincus S, Paoletti E, Laegreid W, Shope R, Mason P. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virol 1992; 190: 454-8.
19. Tartaglia J, Cox W, Pincus S, Paoletti E. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. In: Brown F, ed. Recombinant vectors in vaccine development. Dev Biol Stand, Basel: Karger, 1994; 82: 125-9.
20. Brockmeier S, Lager K, Tartaglia J, Riviere M, Paoletti E, Mengeling W. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Micro 1993; 38: 41-58.
21. Esposito J, Knight, J, Shaddock J, Novembre F, Bauer G. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virol 1988; 165: 313-6.
22. Webster R, Kawaoka Y, Taylor J, Weinberg R, Paoletti E. Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 1991; 9: 303-7.
23. Nazarian K, Lee L, Yanagida N, Ogawa R. Protection against Marek's disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek's disease virus. J Virol 1992; 66: 1409-13.
24. Taylor J, Edbauer C, Rey-Senelonge A, et al. Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol 1990; 64: 1441-50.
25. Edbauer C, Weinberg R, Taylor J, et al. Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene. Virol 1990; 179: 901-4.
26. Taylor J, Weinberg R, Languet B, Desmettre P, Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988; 6: 497-503.
27. Taylor J, Trimarchi C, Weinberg R, et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991; 9: 190-3.
28. Taylor J, Tartaglia J, Moran T, et al. The role of poxvirus vectors in influenza vaccine development. In: Proceedings of the Third International Symposium on Avian Influenza. University of Wisconsin-Madison Extension Duplicating Services, 1992.
29. Tartaglia J, Jarrett O, Neil J, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993; 67: 2370-5.
30. Cadoz M, Strady A, Meignier B, et al. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992; 339: 1429-32.
31. Pialoux G, Excler J, Riviere Y, et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retro 1995; 11: 373-81.
32. MN env gene. J Infect Dis 1995; 171: 1623-7.
33. Taylor J, Tartaglia J, Riviere M, et al. Applications of canarypox (ALVAC) vectors in human and veterinary vaccination. In: Brown F, ed. Dev Biol Stand Basel: Karger, 1994; 82: 131-5.
34. Plotkin S, Cadoz M, Meignier B. The safety and use of canarypox vectored vaccines. Dev Biol Stand, Basel, Karger, 1995: 165-70.
35. Cooney E, Collier A, Greenberg P, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991; 337: 567-72.
36. Lotze M, Chang A, Seipp C, Simpson C, Vetto J, Rosenberg S. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. JAMA 1986; 526: 3117-24.
37. Hodge J, Abrams S, Schlom J, Kantor J. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994; 54: 5552-5.
38. van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
39. Toso J, Oei C, Oshidari F, et al. MAGE-1 specific CTLp present among tumor infiltrating lymphocytes from a patient with breast cancer: Characterization and antigen-specific activation. Cancer Res 1996; (In press).
40. Tartaglia J, Taylor J, Cox W, et al. Novel poxvirus strains as research tools and vaccine vectors. In: Koff W, Wong-Staal F, Kennedy R, eds. AIDS research reviews. New York: Marcel Dekker, 1993; 3: 361-78.
41. Perricaudet M, Stratford-Perricaudet L. Adenovirus-mediated in vivo gene therapy. In: Vos J, ed. Viruses in human gene therapy. Durham, North Carolina: Carolina Academic Press, 1995: 1-32.
42. Berkner K, Sharp P. Preparation of adenovirus recombinants using plasmids of viral DNA. In: Gluzman Y, ed. Eukaryotic viral vectors. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory, 1982: 193-8.
43. Zabner J, Couture L, Gregory R, Graham S, Smith A, Welsh M. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 1993; 75: 207-16.
44. Dai Y, Schwarz E, Gu D, Zhang W, Sarvetnick N, Verma I. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-5.
45. Kay M, Landen C, Rothenberg S, et al. In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-7.
46. Wesseling J, Godeke G, Schijns V, et al. Mouse hepatitis virus spike and nucleocapsid proteins expressed by adenovirus vectors protect mice against a lethal infection. J Gen Virol 1993; 74: 2061-9.
47. Prevec L, Campbell J, Christie B, Belbeck L, Graham F. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990; 161: 27-30.
48. Krilov L, Rubin L, Frogel M, et al. Disseminated adenovirus infection with hepatic necrosis in patients with human immunodeficiency virus infection and other immunodeficiency states. Rev Infect Dis 1990; 12: 303-7.
49. Stanley E, Jackson G. Spread of enteric live adenovirus type 4 vaccine in married couples. J Infect Dis 1969; 119: 51-9.
50. Mueller R, Muldoon R, Jackson G. Communicability of enteric live adenovirus type 4 vaccine in families. J Infect Dis 1969; 119: 60-6.
51. Ginsberg H, Lundholm-Beauchamp U, Horswood R, et al. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 1989; 86: 3823-7.
52. Tacket C, Losonsky G, Lubeck M, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1992; 10: 673-6.
53. Natuk R, Lubeck M, Chanda P, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retro 1993; 9: 395-404.
54. Ragot T, Finerty S, Watkins P, Perricaudet M, Morgan A. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 1993; 74: 501-7.
55. Eloit M, Adam M. Isogenic adenoviruses type 5 expressing or not expressing the E1A gene: efficiency as virus vectors in the vaccination of permissive and non-permissive species. J Gen Virol 1995; 76: 1583-9.
56. Rosenfeld M, Toshimura K, Trapnelli B. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-55.
57. Grubb B, Pickles R, Ye H, et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371: 802-6.
58. Knowles M, Hohneker K, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995; 333: 823-31.
59. Yao S, Wilson J, Nabel E, Kurachi H, Hachiya H, Kurachi K. Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B. Proc Natl Acad Sci USA 1991; 88: 8101-5.
60. Dai Y, Roman M, Naviaux R, Verma I. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 1992; 89: 10892-5.
61. Armentano D, Thompson A, Darlington G, Woo S. Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: Potential for gene therapy of hemophilia B. Proc Natl Acad Sci USA 1990; 87: 6141-5.
62. Stratford-Perricaudet L, Makeh I, Perricaudet M, Briand P. Widespread long-term gene transfer to mouse skeletal muscles and heart. J Clin Invest 1992; 90: 626-30.
63. Bennett J, Wilson J, Sun D, Forbes B, Maguire A. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Visual Sci 1993; 35: 2535-42.
64. Imperiale M, Kao H, Feldman L, Nevins J, Strickland S. Common control of the heat shock gene and early adenovirus genes: Evidence for a cellular E1A-like activity. Mol Cell Bio 1984; 4: 867-74.
65. Yang Y, Ertl H, Wilson J. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-42.
66. Yang Y, Nunes F, Barencsi K, Gonczol E, Engelhardt J, Wilson J. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-9.
67. Engelhardt J, Ye X, Doranz B, Wilson J, Ablation of E2a in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-200.
68. Haddada H, Ragot T, Cordier L, Duffour M, Perricaudet M. Adenoviral interleukin-2 gene transfer into P815 tumour cells abrogates tumorigenicity and induces antitumoral immunity in mice. Hum Gene Ther 1993; 4: 703-11.
69. Cordier L, Duffour M, Sabourin J, et al. Complete recovery of mice from a pre-established tumour by direct intratumoral delivery of an adenovirus vector harbouring the murine IL-2 gene. Gene Ther 1995; 2: 16-21.
70. Morgan R. Retroviral vectors in human gene therapy. In: Vos J, ed, Viruses in human gene therapy. Durham North Carolina: Carolina Academic Press, 1995; 77-107.
71. Meerovitch K, Sonenberg N. Internal initiation of picornavirus RNA translation. Seminars Virol 1993; 4: 217-27.
72. Miller A, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-902.
73. Hunt L, Brown D, Robinson H, Naeve C, Webster R. Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections. J Virol 1988; 62: 3014-19.
74. Blaese R, Anderson W. The ADA human gene therapy clinical protocol. Hum Gene Ther 1990; 1: 327-62.
75. - SCID: Initial trial results after 4 years. Science 1995; 270: 475-80.
76. Kay M, Rothenberg S, Landen C, et al. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-19.
77. Wilson J, Chowdhury N, Grossman M, et al. Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. Proc Natl Acad Sci USA 1990; 87: 8437-41.
78. Ferry N, Duplessis O, Houssin D, Danos O, Heard J. Retroviral-mediated gene transfer into hepatocytes in vivo. Proc Natl Acad Sci USA 1991; 88: 8377-81.
79. Yee J, Miyanohara A, LaPorte P, Bouic K, Burns J, Friedmann T. A general method for the generation of high-titer, pantropic retroviral vectors: Highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 1994; 91: 9564-8.
80. Miyanohara A, Yee J, Bouic K, LaPorte P, Friedmann T. Efficient in vivo transduction of the neonatal mouse liver with pseudotyped retroviral vectors. Gene Ther 1995; 2: 138-42.
81. Watanabe Y, Kuribayashi K, Miyatake S, et al. Exogenous expression of mouse interferon cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci USA 1989; 86: 9456-60.
82. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-24.
83. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-43.
84. Fakhrai H, Shawler D, Gjerset R, et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: Effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 1995; 6: 591-601.
85. Samulski R. Adeno-associated viral vectors. In Vos J, ed. Viruses in human gene therapy. Durham, North Carolina: Carolina Academic Press, 1995: 53-76.
86. Flotte T, Afione S, Conrad, C, et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-17.
87. Morgan R, Anderson W. Human gene therapy. Ann Rev Bio 1993; 62: 191-217.